Empagliflozin, a key diabetes medication sold under the brand name Jardiance, was originally discovered by Boehringer Ingelheim. The good news is that its patent protection in India ended on March 11, 2025, paving the way for more affordable generic versions.
India is often called the diabetes capital of the world, with over 77 million people affected. Until now, Jardiance was priced at around ₹59 per tablet, but with generic versions entering the market, the cost is expected to drop significantly to around ₹5.50 per tablet. This price reduction is a huge relief for many patients who rely on the medicine for daily diabetes management.
Empagliflozin helps control diabetes by preventing the kidneys from reabsorbing glucose, allowing excess sugar to be eliminated through urine. This frequent urination, which is a common side effect, also helps lower blood pressure by reducing sodium levels in the body. As a result, the medicine is beneficial for both diabetes and high blood pressure management.
Leading Indian pharmaceutical companies like Alkem and Glenmark have stepped forward to manufacture generic versions of empagliflozin. However, some medicines in the market have been flagged as substandard by the Central Drugs Standard Control Organization (CDSCO), raising concerns about quality and effectiveness.
SayaCare ensures that only high-quality, tested medicines reach patients. The company sources medicines directly from manufacturers and sends every batch to a government-approved NABL-certified lab for testing before sale. Medicines are then stored in a temperature-controlled warehouse to maintain their effectiveness. By bypassing the traditional supply chain, SayaCare sells medicines at prices lower than the MRP, ensuring affordability without compromising on quality.
With SayaCare, patients not only get access to affordable medication but also receive quality-assured medicines that have been independently tested. This initiative helps patients save up to 90 percent on MRP while ensuring they receive safe and effective treatment.
Mahak Phartyal completed her bachelor's in pharmacy from Veer Madho Singh Bhandari Uttarakhand Technical University. She previously worked as a Medical Writer at Meril Life Sciences, where she wrote numerous scientific abstracts for conferences such as India Live 2024 and the European Society of Cardiology (ESC). During her college years, she developed a keen research interest and published an article titled “Preliminary Phytochemical Screening, Physicochemical and Fluorescence Analysis of Nyctanthes arbor-tristis and Syzygium cumini Leaves.”
Mahak Phartyal completed her bachelor’s in pharmacy from Veer Madho Singh Bhandari Uttarakhand Technical University. She previously worked as a Medical Writer at Meril Life Sciences, where she wrote numerous scientific abstracts for conferences such as India Live 2024 and the European Society of Cardiology (ESC). During her college years, she developed a keen research interest and published an article titled “Preliminary Phytochemical Screening, Physicochemical and Fluorescence Analysis of Nyctanthes arbor-tristis and Syzygium cumini Leaves.”
